Treatment of children and adolescents with multiple sclerosis

References

• Lublin FD. The diagnosis of multiple sclerosis. Curr. Opin. Neurol. 15, 253–256 (2002).
   PubMed Web of Science ®Google Scholar
• O’Connor P. Key issues in the diagnosis and treatment of multiple sclerosis. An overview. Neurology 59, S1–33 (2002).
   PubMed Web of Science ®Google Scholar
• vanderMie I, Ponsonby AL, Dwyer T et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. Br. Med. J. 327, 316 (2003).
   PubMedGoogle Scholar
• DeLuca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J. 15, 2579–2585 (2001).
   PubMed Web of Science ®Google Scholar
• Meehan TF, DeLuca HF. The vitamin D receptor is necessary for 1α, 25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Arch. Biochem. Biophys. 408, 200–204 (2002).
   PubMed Web of Science ®Google Scholar
• Holick MF. Vitamin D: a millenium perspective. J. Cell. Biochem. 88, 296–307 (2003).
   PubMed Web of Science ®Google Scholar
• Ascherio A, Munch M. Epstein–Barr virus and multiple sclerosis. Epidemiology 11, 220–224 (2000).
   PubMed Web of Science ®Google Scholar
• Alotaibi S, Kennedy J, Tellier R, Stephens D, Banwell B. Epstein–Barr virus in pediatric multiple sclerosis. JAMA 291, 1875–1879 (2004).
   PubMed Web of Science ®Google Scholar
• Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D. Early onset multiple sclerosis: a longitudinal study. Neurology 59, 1006–1010 (2002).
   PubMed Web of Science ®Google Scholar
• Boutin B, Esquivel E, Mayer M, Chaumet S, Ponsot G, Arthuis M. Multiple sclerosis in children: report of clinical and paraclinical features of 19 cases. Neuropediatrics 19, 118–123 (1988).
   PubMed Web of Science ®Google Scholar
• Cole GF, Stuart CA. A long perspective on childhood multiple sclerosis. Dev. Med. Child Neurol. 37, 661–666 (1995).
   PubMed Web of Science ®Google Scholar
• Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 12, 2407–2422 (2000).
   Google Scholar
• Duquette P, Murray TJ, Pleines J et al. Multiple sclerosis in childhood: clinical profile in 125 patients. J.Pediatr. 111, 359–363 (1987).
   PubMed Web of Science ®Google Scholar
• Gall J, Hayles A, Siekert R, Keith H. Multiple sclerosis in children: a clinical study of 40 cases with onset in childhood. Pediatrics 21, 703–709 (1958).
   PubMed Web of Science ®Google Scholar
• Ghezzi A, Deplano V, Faroni J et al. Multiple sclerosis in childhood: clinical features of 149 cases. Mult. Scler. 3, 43–46 (1997).
   PubMed Web of Science ®Google Scholar
• Guilhoto LM, Osorio CA, Machado LR et al. Pediatric multiple sclerosis report of 14 cases. Brain Dev. 17, 9–12 (1995).
   PubMedGoogle Scholar
• Gusev E, Boiko A, Bikova O et al. The natural history of early onset multiple sclerosis: comparison of data from Moscow and Vancouver. Clin. Neurol. Neurosurg. 104, 203–207 (2002).
   PubMed Web of Science ®Google Scholar
• Pinhas-Hamiel O, Barak Y, Siev-Ner I, Achiron A. Juvenile multiple sclerosis: clinical features and prognostic characteristics. J. Pediatr. 132, 735–737 (1998).
   PubMed Web of Science ®Google Scholar
• Ozakbas S, Idiman E, Baklan B, Yulug B. Childhood and juvenile onset multiple sclerosis: clinical and paraclinical features. Brain Dev. 25, 233–236 (2003).
   PubMed Web of Science ®Google Scholar
• Selcen D, Anlar B, Renda Y. Multiple sclerosis in childhood: report of 16 cases. Eur. Neurol. 36, 79–84 (1996).
   PubMed Web of Science ®Google Scholar
• Simone IL, Carrara D, Tortorella C et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology 59, 1922–1928 (2002).
   PubMed Web of Science ®Google Scholar
• Sindern E, Haas J, Stark E, Wurster U. Early onset MS under the age of 16: clinical and paraclinical features. Acta Neurol. Scand. 86, 280–284 (1992).
   PubMed Web of Science ®Google Scholar
• Hanefeld F, Bauer HJ, Christen HJ, Kruse B, Bruhn H, Frahm J. Multiple sclerosis in childhood: report of 15 cases. Brain Dev. 13, 410–416 (1991).
   PubMed Web of Science ®Google Scholar
• Ghezzi A, Pozzilli C, Liguori M et al. Prospective study of multiple sclerosis with early onset. Mult. Scler. 8, 115–118 (2002).
   PubMed Web of Science ®Google Scholar
• Ruggieri M, Polizzi A, Pavone L, Grimaldi LM. Multiple sclerosis in children under 6 years of age. Neurology 53, 478–484 (1999).
   PubMed Web of Science ®Google Scholar
• Banwell BL. Pediatric multiple sclerosis. Curr. Neurol. Neurosci. Rep. 4, 245–252 (2004).
   PubMedGoogle Scholar
• Boiko AN, Guseva ME, Guseva MR et al. Clinico-immunogenetic characteristics of multiple sclerosis with optic neuritis in children. J. Neurovirol. 6(Suppl. 2), S152–S155 (2000).
   Google Scholar
• Mikaeloff Y, Suissa S, Vallee L et al. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J. Pediatr. 144, 246–252 (2004).
   PubMed Web of Science ®Google Scholar
• Hanefeld F. Multiple sclerosis in childhood. Curr. Opin. Neurol. Neurosurg. 5, 359–363 (1992).
   PubMedGoogle Scholar
• Lucchinetti CF, Kiers L, O’Duffy A et al. Risk factors for developing multiple sclerosis after childhood optic neuritis. Neurology 49, 1413–1418 (1997).
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53, 1107–1114 (1999).
   PubMed Web of Science ®Google Scholar
• Jeffery AR, Buncic JR. Pediatric Devic’s neuromyelitis optica. J. Pediatr. Ophthalmol. Strabismus. 33, 223–229 (1996).
   PubMed Web of Science ®Google Scholar
• Lennon VA, Wingerchuk DM, Kryzer TJ et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364, 2106–2112 (2004).
   PubMed Web of Science ®Google Scholar
• Tenembaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology 59, 1224–1231 (2002).
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM. Postinfectious encephalomyelitis. Curr. Neurol. Neurosci. Rep. 3, 256–264 (2003).
   PubMedGoogle Scholar
• Lucchinetti CF, Brueck W, Rodriguez M, Lassmann H. Multiple sclerosis: lessons from neuropathology. Semin. Neurol. 18, 337–349 (1998).
   PubMed Web of Science ®Google Scholar
• Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol.. 12, 295–302 (1999).
   PubMed Web of Science ®Google Scholar
• Trapp BD, Bo L, Mork S, Chang A. Pathogenesis of tissue injury in MS lesions. J. Neuroimmunol. 98, 49–56 (1999).
   PubMed Web of Science ®Google Scholar
• Yong VW. Prospects for neuroprotection in multiple sclerosis. Front Biosci. 9, 864–872 (2004).
   PubMedGoogle Scholar
• Wang HY, Matsui M, Araya S, Onai N, Matsushima K, Saida T. Immune parameters associated with early treatment effects of high-dose intravenous methylprednisolone in multiple sclerosis. J. Neurol. Sci. 216, 61–66 (2003).
   PubMed Web of Science ®Google Scholar
• Andersson PB, Goodkin DE. Glucocorticosteroid therapy for multiple sclerosis: a critical review. J. Neurol. Sci. 160, 16–25 (1998).
   PubMed Web of Science ®Google Scholar
• Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology 49, 1404–1413 (1997).
   PubMed Web of Science ®Google Scholar
• Metz LM, Sabuda D, Hilsden RJ, Enns R, Meddings JB. Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis. Neurology 53, 2093–2096 (1999).
   PubMed Web of Science ®Google Scholar
• Morrow SA, Stoian CA, Dmitrovic J, Chan SC, Metz LM. The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology 63, 1079–1080 (2004).
   PubMed Web of Science ®Google Scholar
• Stangel M, Toyka KV, Gold R. Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. Arch. Neurol. 56, 661–663 (1999).
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291, 2367–2375 (2004).
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Fazekas F, Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur. J. Neurol. 9, 557–563 (2002).
   PubMed Web of Science ®Google Scholar
• Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomized placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 349, 589–593 (1997).
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Wanscher B, Jensen CV et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50, 1273–1281 (1998).
   PubMed Web of Science ®Google Scholar
• Achiron A, Kishner I, Sarova-Pinhas I et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch. Neurol. 61, 1515–1520 (2004).
   PubMed Web of Science ®Google Scholar
• Noseworthy JH, O’Brien PC, Petterson TM et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 56, 1514–1522 (2001).
   PubMed Web of Science ®Google Scholar
• Hommes OR, Sorensen PS, Fazekas F et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 364, 1149–1156 (2004).
   PubMed Web of Science ®Google Scholar
• Visser LH, Beekman R, Tijssen CC et al. A randomized, double-blind, placebo-controlled pilot study of intravenous immune globulins in combination with intravenous methylprednisolone in the treatment of relapses in patients with MS. Mult. Scler. 10, 89–91 (2004).
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Haas J, Sellebjerg F, Olsson T, Ravnborg M. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 63, 2028–2033 (2004).
   PubMed Web of Science ®Google Scholar
• Hahn JS, Siegler DJ, Enzmann D. Intravenous gammaglobulin therapy in recurrent acute disseminated encephalomyelitis. Neurology 46, 1173–1174 (1996).
   PubMed Web of Science ®Google Scholar
• Nishikawa M, Ichiyama T, Hayashi T, Ouchi K, Furukawa S. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. Pediatr. Neurol. 21, 583–586 (1999).
   PubMed Web of Science ®Google Scholar
• Murthy SN, Faden HS, Cohen ME, Bakshi R. Acute disseminated encephalomyelitis in children. Pediatrics 110, e21 (2002).
   PubMed Web of Science ®Google Scholar
• Pradhan S, Gupta RP, Shashank S, Pandey N. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. J. Neurol. Sci. 165, 56–61 (1999).
   PubMed Web of Science ®Google Scholar
• Apak RA, Anlar B, Saatci I. A case of relapsing acute disseminated encephalomyelitis with high dose corticosteroid treatment. Brain Dev. 21, 279–282 (1999).
   PubMed Web of Science ®Google Scholar
• Sahlas DJ, Miller SP, Guerin M, Veilleux M, Francis G. Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology 54, 1370–1372 (2000).
   PubMed Web of Science ®Google Scholar
• Finsterer J, Grass R, Stollberger C, Mamoli B. Immunoglobulins in acute, parainfectious, disseminated encephalo-myelitis. Clin. Neuropharmacol. 21, 258–261 (1998).
   PubMed Web of Science ®Google Scholar
• Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus. Med. Rev. 17, 241–251 (2003).
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, O’Brien PC, Petterson TM et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann. Neurol. 46, 878–886 (1999).
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann. Neurol. 37, 7–15 (1995).
   PubMed Web of Science ®Google Scholar
• Yong VW, Chabot S, Stuve O, Williams G. Interferon β in the treatment of multiple sclerosis: mechanisms of action. Neurology 51, 682–689 (1998).
   PubMed Web of Science ®Google Scholar
• The IFN-B Multiple Sclerosis Study Group. Interferon β1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43, 655–661 (1993).
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon β1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39, 285–294 (1996).
   PubMed Web of Science ®Google Scholar
• PRISMS. Randomised double-blind placebo-controlled study of interferon β1a in relapsing-remitting ms. Lancet 352, 1498–1504. (2000).
   Web of Science ®Google Scholar
• PRISMS4. Long-term efficacy of interferon-β1a in relapsing MS. Neurology 56, 1628–1636 (2001).
   PubMed Web of Science ®Google Scholar
• Durelli L, Verdun E, Barbero P et al. Every-other-day interferon β1b versus once-weekly interferon β1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359, 1453–1460 (2002).
   PubMed Web of Science ®Google Scholar
• Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP. A prospective, open-label treatment trial to compare the effect of IFN-β1a (Avonex®), IFN-β1b (Betaseron®), and glatiramer acetate (Copaxone®) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy. Mult. Scler. 7, 349–353 (2001).
   PubMed Web of Science ®Google Scholar
• Rudick RA. Biologic impact of interferon antibodies, and complexities in assessing their clinical significance. Neurology 61, S31–S34 (2003).
   Google Scholar
• Bertolotto A, Gilli F, Sala A et al. Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients. Neurology 60, 634–639 (2003).
   PubMed Web of Science ®Google Scholar
• Vartanian TK, Zamvil SS, Fox E, Sorensen PS. Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. Neurology 63, S42–S49 (2004).
   PubMed Web of Science ®Google Scholar
• Adams AB, Tyor WR, Holden KR. Interferon β1b and childhood multiple sclerosis. Pediatr. Neurol.21, 481–483 (1999).
   PubMed Web of Science ®Google Scholar
• Etheridge LJ, Beverley DW, Ferrie C, McManus E. The use of interferon β in relapsing-remitting multiple sclerosis. Arch. Dis. Child. 89, 789–791 (2004).
   PubMed Web of Science ®Google Scholar
• Mikaeloff Y, Moreau T, Debouverie M et al. Interferon-β treatment in patients with childhood-onset multiple sclerosis. J. Pediatr. 139, 443–446 (2001).
   PubMed Web of Science ®Google Scholar
• Waubant E, Hietpas J, Stewart T et al. Interferon β1a in children with multiple sclerosis is well-tolerated. Neuropediatrics 32, 211–213 (2001).
   PubMed Web of Science ®Google Scholar
• Pohl D, Rostasy K, Hanefeld F, Gartner J. The use of interferon-β1a (Rebif) in children and adolescents with multiple sclerosis. Mult. Scler. 10(Suppl. 2), 250 (2004).
   Google Scholar
• Krupp LB, Banwell BL, Boiko A et al. Treatment of childhood and adolescent MS with interferon-β1b. Mult. Scler. 10(Suppl. 2), 245 (2004).
   PubMedGoogle Scholar
• Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon β1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 343, 898–904 (2000).
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357, 1576–1582 (2001).
   PubMed Web of Science ®Google Scholar
• Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56, 702–708 (2001).
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA et al. Co-polymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind placebo-controlled trial. The co-polymer 1 Multiple Sclerosis Study Group. Neurology 45, 1268–1276 (1995).
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. 49, 290–297 (2001).
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Ford CC et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Co-polymer 1 Multiple Sclerosis Study Group. Mult. Scler. 6, 255–266 (2000).
   PubMed Web of Science ®Google Scholar
• Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis. Cochrane. Database. Syst. Rev. CD004678 (2004).
   Google Scholar
• Millefiorini E, Gasperini C, Pozzilli C et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J. Neurol. 244, 153–159 (1997).
   PubMed Web of Science ®Google Scholar
• Hartung HP, Gonsette R, Konig N et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360, 2018–2025 (2002).
   PubMed Web of Science ®Google Scholar
• The Canadian Co-operative Multiple Sclerosis Study Group. The Canadian co-operative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337, 441–446 (1991).
   PubMed Web of Science ®Google Scholar
• Weiner HL, Mackin GA, Orav EJ et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Co-operative Multiple Sclerosis Treatment Group. Neurology 43, 910–918 (1993).
   PubMed Web of Science ®Google Scholar
• Smith D. Preliminary analysis of a trial of pulse cyclophosphamide in IFN-β-resistant active MS. J. Neurol. Sci. 223, 73–79 (2004).
   PubMed Web of Science ®Google Scholar
• Hauser SL, Dawson DM, Lehrich JR et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N. Engl. J. Med. 308, 173–180 (1983).
   PubMed Web of Science ®Google Scholar
• Yudkin PL, Ellison GW, Ghezzi A et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 338, 1051–1055 (1991).
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S. Non-specific immunosuppressants in the treatment of multiple sclerosis. Clin. Neurol. Neurosurg. 106, 263–269 (2004).
   PubMed Web of Science ®Google Scholar
• Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil®) for the treatment of fatigue in multiple sclerosis: a two centre Phase 2 study. J. Neurol. Neurosurg. Psychiatry 72, 179–183 (2002).
   PubMed Web of Science ®Google Scholar
• Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch. Neurol. 46, 676–680 (1989).
   PubMed Web of Science ®Google Scholar
• Hyman N, Barnes M, Bhakta B et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double-blind, placebo-controlled, dose ranging study. J. Neurol. Neurosurg. Psychiatry 68, 707–712 (2000).
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Cohen JA. Emerging therapies for multiple sclerosis. Neurologist2, 342–355 (1996).
   Web of Science ®Google Scholar
• Solaro C, Lunardi GL, Capello E et al. An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology 51, 609–611 (1998).
   PubMed Web of Science ®Google Scholar
• Miller DH, Khan OA, Sheremata WA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348, 15–23 (2003).
   PubMed Web of Science ®Google Scholar
• Neuhaus O, Strasser-Fuchs S, Fazekas F et al. Statins as immunomodulators: comparison with interferon-β1b in MS. Neurology 59, 990–997 (2002).
   PubMed Web of Science ®Google Scholar
• Vollmer T, Key L, Durkalski V et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363, 1607–1608 (2004).
   PubMed Web of Science ®Google Scholar
• McCrindle BW, Helden E, Cullen-Dean G, Conner WT. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatr. Res. 51, 715–721 (2002).
   PubMed Web of Science ®Google Scholar
• de Jongh S, Lilien MR, Op’t Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J. Am. Coll. Cardiol. 40, 2117–2121 (2002).
   PubMed Web of Science ®Google Scholar
• Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu. Rev. Med. 55, 477–503 (2004).
   PubMed Web of Science ®Google Scholar
• Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in Neurology. Lancet Neurol. 3, 744–751 (2004).
   PubMed Web of Science ®Google Scholar